Tarsus Pharmaceuticals, Inc (TARS) released Loss for fourth quarter that decreased from last year and beat the Street estimates.
The company's earnings totaled -$23.113 million, or -$0.60 per share. This compares with -$41.902 million, or -$1.31 per share, last year.
Analysts on average had expected the company to earn -$0.82 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period rose 407.9% to $66.408 million from $13.076 million last year.
Tarsus Pharmaceuticals, Inc earnings at a glance (GAAP) :
-Earnings: -$23.113 Mln. vs. -$41.902 Mln. last year.-EPS: -$0.60 vs. -$1.31 last year.-Revenue: $66.408 Mln vs. $13.076 Mln last year.
The company’s fourth-quarter sales were driven by around 58,500 bottles of XDEMVY dispensed to patients, compared with approximately 15,700 bottles dispensed in the same period last year.
TARS was up by 9.24 percent at $49.75 in the pre-market trade on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.